IDEAYA Biosciences (NASDAQ:IDYA) SVP Paul A. Stone bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were acquired at an average price of $10.00 per share, with a total value of $2,500,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NASDAQ:IDYA opened at $6.60 on Thursday. The firm’s 50 day simple moving average is $7.38. IDEAYA Biosciences has a twelve month low of $6.12 and a twelve month high of $16.90.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, August 12th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.66). On average, equities analysts forecast that IDEAYA Biosciences will post -3.02 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $11,369,000. Victory Capital Management Inc. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $1,453,000. Cubist Systematic Strategies LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $49,000. Point72 Asset Management L.P. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $1,948,000. Finally, Vanguard Group Inc. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $349,000. Institutional investors own 0.62% of the company’s stock.

Several analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “neutral” rating and a $15.00 target price for the company. Jefferies Financial Group assumed coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “buy” rating and a $14.00 target price for the company. Finally, Citigroup assumed coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “buy” rating and a $20.00 target price for the company.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.